Earnings

Quarterly results, guidance, estimates

50 stories

In the last 7 days, Earnings tracked 14 stories — 14% positive, 7% negative, 79% neutral sentiment, averaging 5.4/10 impact.

Stories appear on this page because our classification stage assigned them this category as their primary topic — each story receives exactly one category per niche, chosen from a fixed list, so a story that touches both a funding round and a product launch in the same week sorts into whichever category best matches its dominant subject, not both. This keeps each category page focused on one beat rather than a blend of unrelated developments, and applies the same source-verification standard used across every story on this site. Sentiment measures the directional read of each development for this category specifically, not the tone of the reporting, and impact weights how consequential a development is — regulatory, financial, or operational — rather than how widely it was syndicated across outlets.

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

Neutral 5

Specialty Pharma Resilience: Cumberland and Rigel Navigate Q4 Headwinds

Cumberland and Rigel Pharmaceuticals reported Q4 2025 results, highlighting strategic shifts toward high-margin specialty products and oncology expansions. While Cumberland focuses on hospital-channel optimization, Rigel is doubling down on its hematology-oncology portfolio to drive long-term growth.

Verified by 2 sources
Bullish 6

Palladyne AI and Burlington Surpass Estimates as FY26 Outlooks Solidify

Palladyne AI and Burlington Stores both delivered strong quarterly performances, exceeding analyst expectations on both revenue and earnings. While Palladyne AI reaffirmed its long-term trajectory for fiscal 2026, Burlington introduced a robust new guidance framework, signaling confidence in the off-price retail and AI software sectors.

Verified by 2 sources
Neutral 5

OmniAb and PepGen Q4 Results Highlight Divergent Biotech Growth Strategies

OmniAb and PepGen reported full-year 2025 results, showcasing the health of the antibody discovery and neuromuscular therapeutics sectors. While OmniAb focuses on platform scalability and royalty streams, PepGen emphasizes clinical execution and cash preservation for its lead candidates.

Verified by 2 sources
Bullish 6

SaaS Resilience: Okta Hits $3B Milestone as Ooma Pivots to Enterprise

Okta and Ooma both reported strong Q4 2026 results, highlighting a broader sector trend of shifting toward higher-margin enterprise services and AI integration. While Okta surpassed the $3 billion annual contract value milestone, Ooma successfully integrated key acquisitions to accelerate its transition from residential to business-centric revenue.

Verified by 2 sources
Neutral 5

Daktronics Q3 2026 Earnings: Revenue Surges 22% as MLB Projects Drive Growth

Daktronics, Inc. reported a 21.6% increase in sales to $181.9 million for its fiscal 2026 third quarter, successfully swinging from a prior-year operating loss to a $1.9 million profit. The company's performance was bolstered by a 25% surge in product backlog, reaching $342.3 million, driven by major sports stadium installations and improved operational efficiencies.

Verified by 4 sources

Source: Globenewswire_fr · Benzinga

Bullish 6

Stem Achieves First Profitable Year as Software Pivot Drives Record Margins

Stem (STEM) reached a critical financial milestone in Q4 2025, reporting its first full year of positive adjusted EBITDA and operating cash flow. The results highlight a successful strategic pivot toward high-margin software and services, which now account for over half of total revenue.

Verified by 14 sources
Neutral 5

ImmuCell and Pinetree Capital Reveal 2025 Results Amid Scaling Shift

ImmuCell (ICCC) has issued its preliminary 2025 financial results, highlighting a year of operational scaling for its bovine immunity products. Simultaneously, major shareholder Pinetree Capital Ltd released audited figures and expanded its board, signaling a period of strategic consolidation for the animal health biotech and its primary backer.

Verified by 2 sources
Neutral 5

Asana and AST SpaceMobile Signal Growth Shifts in Q4 Earnings Reports

Asana, Inc. and AST SpaceMobile, Inc. released quarterly results highlighting divergent paths in the SaaS and space telecommunications sectors. While Asana navigates a maturing market with AI-driven enterprise tools, AST SpaceMobile continues its capital-intensive push toward global satellite connectivity.

Verified by 2 sources
Very Bullish 6

Datadog and agilon health Surge as Growth Narratives Re-Accelerate

Datadog and agilon health shares experienced significant rallies on March 4, 2026, signaling a robust appetite for high-growth cloud infrastructure and value-based healthcare models. The moves highlight a broader market shift toward companies demonstrating both scale and operational leverage in complex regulatory and technological environments.

Verified by 2 sources
Neutral 5

Earnings Divergence: Real Brokerage Scales Up as Rayonier Faces Widening Losses

The Real Brokerage Inc. (REAX) reported continued agent expansion and revenue growth in Q4 2025, while Rayonier Advanced Materials (RYAM) struggled with a widening net loss and ongoing debt restructuring. These results highlight a stark contrast between high-growth tech-enabled real estate platforms and legacy industrial materials firms facing margin pressure.

Verified by 2 sources
Neutral 5

Small-Cap Earnings Spotlight: Lexicon and Ituran Navigate Q4 Inflection Points

Investors are bracing for Q4 2025 results from Lexicon Pharmaceuticals and Ituran Location, two small-cap players facing critical operational milestones. While Lexicon seeks to prove the commercial viability of its heart failure treatment, Ituran aims to capitalize on expanding telematics demand in emerging markets.

Verified by 2 sources
Neutral 5

MedTech Earnings: 908 Devices and Strata Critical Medical Signal Diagnostic Shift

908 Devices Inc. and Strata Critical Medical reported Q4 2025 results, highlighting a strategic pivot toward decentralized diagnostics and bioprocessing efficiency. Both companies emphasized recurring revenue growth from consumables as they navigate a complex capital equipment environment.

Verified by 2 sources
Neutral 5

L.B. Foster Hits 7-Year Sales Peak as Infrastructure Tech Pivot Drives Profits

L.B. Foster Company reported its strongest fourth-quarter net sales since 2018, marking a significant milestone in its multi-year transition toward high-margin technology solutions. The results highlight robust profitability growth and operating cash flow, signaling a successful pivot from legacy commodity products.

Verified by 2 sources
Bullish 6

AI Sector Bifurcation: BigBear.ai Struggles as Vertiv Reaches Peak Valuation

Recent earnings reports reveal a widening gap in the AI sector between speculative software plays and essential infrastructure providers. While BigBear.ai faces significant revenue declines and persistent cash burn, Vertiv continues to ride the data center wave, though its stock now appears priced for perfection.

Verified by 2 sources
Bullish 6

Growth Divergence: On Holding and Sportradar Surge as Quanterix Pivots

A wave of Q4 2025 earnings reports reveals a stark performance gap between high-margin consumer platforms and specialized technology firms. While On Holding and Sportradar delivered record margins and aggressive capital returns, Quanterix and BigBear.ai faced organic declines despite achieving critical regulatory and liquidity milestones.

Verified by 6 sources
Neutral 5

Consumer Resilience Tested as Best Buy and Paysafe Post Mixed Q4 Results

Best Buy and Paysafe both reported fourth-quarter results that highlighted a complex consumer landscape, characterized by disciplined spending and shifting demand cycles. Both companies issued 2026 guidance that emphasizes operational efficiency and a strategic pivot toward high-margin services and specialized digital payments.

Verified by 2 sources
Bullish 6

Mobility Sector Resilience: Thor and EVgo Deliver Strong Earnings Beats

Thor Industries and EVgo have both exceeded analyst expectations for the most recent quarter, signaling robust demand in both the recreational vehicle and electric vehicle infrastructure markets. While Thor reaffirmed its existing long-term targets, EVgo’s introduction of its first FY26 outlook suggests a pivotal shift toward operational maturity and predictable growth.

Verified by 2 sources
Neutral 5

Plug Power Q4 Loss Narrows as Green Hydrogen Strategy Gains Operational Traction

Plug Power reported a narrowing loss per share for the fourth quarter, signaling a potential turning point in its multi-year effort to stabilize margins. The results reflect the company's transition toward internal hydrogen production and more disciplined capital allocation amid a challenging macro environment.

Verified by 2 sources
Bullish 7

IonQ Shares Rocket 23% as Q4 Revenue Surges 429% on Commercial Adoption

IonQ reported a massive fourth-quarter earnings beat, driven by a 429% year-over-year revenue surge and a significant shift toward commercial adoption. The company's optimistic 2026 guidance suggests that quantum computing is rapidly moving from experimental phases into a viable enterprise market.

Verified by 3 sources
Neutral 5

Biotech Execution in Focus: Arcturus and Rigel Set for Q4 Earnings Results

Arcturus Therapeutics and Rigel Pharmaceuticals are preparing to report Q4 2025 results, highlighting a pivotal shift from clinical development to commercial execution. Investors are focused on Arcturus's mRNA vaccine rollout in Japan and Rigel's integration of its expanded oncology portfolio.

Verified by 2 sources
Neutral 5

Smith & Nephew and AAON Signal Long-Term Growth in Q4 Earnings Reports

Smith & Nephew and AAON both reported Q4 results that emphasize long-term margin expansion and revenue targets through 2026 and beyond. While AAON faced a mixed quarter with flat revenue growth, Smith & Nephew's multi-year guidance suggests a structural turnaround in its orthopaedics and wound care segments.

Verified by 2 sources
Neutral 6

Workday Earnings Resilience: A Potential Signal for the SaaS Market Bottom

Workday's Q4 results surpassed analyst expectations on both top and bottom lines, driven by a significant surge in AI-related contract value. Despite issuing conservative guidance for the upcoming quarter, the stock's stability suggests that the broader software-as-a-service (SaaS) sector may have reached a valuation floor.

Verified by 2 sources
Neutral 5

Calumet and 1stdibs Q4 Results Highlight Industrial Pivot and Luxury Resilience

Calumet, Inc. reported a Q4 revenue miss of $1.04 billion as it navigates a complex transition to a C-Corp structure and scales its Montana Renewables subsidiary. Meanwhile, 1stdibs.com continues to refine its luxury marketplace model, focusing on operational efficiency amidst a shifting high-end consumer landscape.

Verified by 2 sources
Neutral 5

Spanish Corporates Signal Resilience as Insur and Acciona Energía Post Growth

Spanish real estate developer Inmobiliaria Del Sur (Insur) and renewable energy leader Acciona Energía have reported year-on-year profit growth for the full year 2025. These results underscore a period of operational efficiency and strategic expansion despite broader macroeconomic headwinds in the Eurozone.

Verified by 2 sources
Neutral 5

Getty Images and Designer Brands Slump as Earnings Outlooks Sour

Shares of Getty Images and Designer Brands faced sharp selling pressure on February 27, 2026, following disappointing financial updates. Both companies are grappling with structural shifts in their respective industries, from AI-driven disruption in digital media to a cooling consumer environment in retail footwear.

Verified by 2 sources
Bullish 7

Dell Shares Surge 17.5% as AI Server Revenue Forecast Doubles by FY27

Dell Technologies shares reached a three-month high after the company issued a bullish forecast projecting its AI-optimized server revenue will more than double by fiscal year 2027. This 17.5% stock surge underscores the intensifying demand for high-performance computing infrastructure as enterprises transition from AI experimentation to full-scale deployment.

Verified by 2 sources

Source: marketscreener.com · livemint.com

Neutral 5

Healthcare Services Resilience: Acadia and Spok Signal Growth in 2025 Year-End

Acadia Healthcare and Spok Holdings have released their year-end 2025 financial results, highlighting a period of operational stabilization and strategic pivot. While Acadia continues to navigate regulatory headwinds through facility expansion, Spok remains focused on its high-margin software transition and shareholder returns.

Verified by 2 sources
Neutral 5

Globant Revises 2026 Guidance Amid Shifting Digital Transformation Demand

Globant (NYSE: GLOB) has issued updated earnings guidance for the first quarter and full fiscal year 2026, following a period of significant stock volatility. The update comes on the heels of a February 19 analyst downgrade that saw shares gap down, signaling a recalibration of growth expectations in the AI and blockchain consulting sectors.

Verified by 3 sources

Source: themarketsdaily.com · tickerreport.com

Neutral 5

CRA International and Collegium Pharma Signal Resilience in Q4 2025 Results

CRA International (CRAI) and Collegium Pharmaceutical (COLL) both reported strong Q4 2025 results, highlighting a robust environment for specialized consulting and chronic pain management. While CRAI benefited from record headcount and high utilization in antitrust and litigation, Collegium demonstrated the continued commercial durability of its Belbuca and Xtampza ER franchises.

Verified by 2 sources
Neutral 5

Q4 Earnings Analysis: ACADIA and Alkami Navigate Growth and Market Volatility

ACADIA Pharmaceuticals and Alkami Technology reported Q4 results that highlight divergent paths for mid-cap growth entities. While ACADIA focuses on the commercial scaling of its rare disease portfolio, Alkami is battling a significant stock correction despite beating revenue expectations.

Verified by 2 sources
Bearish 7

Coupang Swings to Surprise Q4 Loss as Record Data Breach Fallout Deepens

Coupang reported a surprise $26 million loss for the fourth quarter, missing analyst estimates as the company grapples with the aftermath of South Korea's largest-ever data breach. Despite an 11% rise in revenue, the e-commerce giant saw its first sequential decline in active users and faces intense regulatory scrutiny alongside a controversial $1.5 billion compensation plan.

Verified by 2 sources
Neutral 5

Warby Parker and Seer Q4 Earnings Highlight Divergent Growth Paths

Warby Parker and Seer, Inc. both reported Q4 2025 results on February 26, 2026, revealing contrasting strategies for growth in the retail and life sciences sectors. While Warby Parker is leveraging physical store expansion to drive vision care services, Seer is navigating the complex commercialization of its proteomics platform.

Verified by 2 sources
Neutral 5

Ginkgo Bioworks Surprises Markets with Significant $0.38 EPS Earnings Beat

Ginkgo Bioworks (NYSE: DNA) outperformed analyst expectations by $0.38 EPS in its latest quarterly report, signaling a potential shift in the company's financial trajectory. The results suggest that the synthetic biology leader's cost-cutting measures and platform scaling are beginning to deliver tangible bottom-line improvements.

Verified by 2 sources

About Finance Earnings coverage

According to our own tracking database, this category has accumulated 463 earnings stories since coverage began. This page aggregates the latest earnings stories within our finance coverage area. Every story is cross-referenced across multiple primary sources, scored for sentiment and operational impact, and timestamped so fresh developments surface first. We track quarterly results, guidance, estimates and surface the angles a domain expert would actually read.

Story selection follows our editorial methodology — impact scoring weights regulatory, financial, and operational developments distinctly. Sentiment is classified across five tiers via supervised classification trained on labeled industry corpora. See our glossary for term definitions and our trends index for longitudinal patterns across the finance beat.

Stories only surface on this page once the classifier scores them at a minimum 35 percent relevance to the category. According to that methodology, reviewed July 2026, this follows multi-source corroboration standards recommended by journalism research bodies such as the Reuters Institute for the Study of Journalism.

See something wrong on this page — a wrong stat, a broken source link, a miscategorized story? Report a data issue.

SignalWhat it tells you
Verified by N sourcesConfidence the story isn't a single-source rumor — N≥2 means the development is independently corroborated.
Impact score (1-10)Estimated regulatory, financial, or operational impact. 8+ indicates a story experienced operators should act on.
SentimentFive-tier classification (very bullish through very bearish) trained on labeled finance-specific corpora.
Time stampRecency. Fresh stories (under 1h) render with a highlighted timestamp; stale stories (≥24h) render dimmed.